scholarly journals New anticoagulants for the prevention of venous thromboembolism

2010 ◽  
pp. 49 ◽  
Author(s):  
Cecilia Becattini ◽  
Lignani ◽  
Agnelli
Keyword(s):  
Venous Thromboembolism ◽  
New Anticoagulants

scholarly journals New anticoagulants for the treatment of venous thromboembolism

2016 ◽  
Vol 42 (2) ◽  
pp. 146-154 ◽  
Author(s):  
Caio Julio Cesar dos Santos Fernandes ◽  
José Leonidas Alves Júnior ◽  
Francisca Gavilanes ◽  
Luis Felipe Prada ◽  
Luciana Kato Morinaga ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Vitamin K Antagonists ◽  
Factor Xa ◽  
Thrombin Inhibitors ◽  
Direct Thrombin Inhibitors ◽  
Vein Thrombosis ◽  
New Anticoagulants ◽  
Acute Pulmonary Thromboembolism ◽  
Deep Vein

Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context.

scholarly journals New insights into treatment of venous thromboembolism

Hematology ◽  
2014 ◽  
Vol 2014 (1) ◽  
pp. 297-305 ◽  
Author(s):  
Stephan Moll
Keyword(s):  
Clinical Practice ◽  
Venous Thromboembolism ◽  
Clinical Management ◽  
Routine Clinical Practice ◽  
Acute Management ◽  
Clinical Context ◽  
High Profile ◽  
New Anticoagulants ◽  
Important Challenge

Abstract Several advances have occurred over the last 2 years in the clinical management of venous thromboembolism (VTE), as evidenced by several high-profile publications in top-tier medical journals. The translation of the knowledge gained into routine clinical practice is an important challenge so that VTE is managed optimally and established and new anticoagulants are used effectively and safely. This chapter reviews issues of VTE treatment from acute management to treatment of long-term complications, addressing new data gained in the last 2 years and putting them into a clinical context, with the goal of improved everyday VTE management.

Incidence of Arterial Embolism in Patients on Treatment with Old and New Anticoagulants for Venous Thromboembolism

2015 ◽  
Vol 41 (02) ◽  
pp. 154-159 ◽  
Author(s):  
Marta Milan ◽  
Sofia Barbar ◽  
Lucia Sarolo ◽  
Chiara Piovella ◽  
Raffaele Pesavento ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Arterial Embolism ◽  
New Anticoagulants

New anticoagulants in the management of venous thromboembolism in women

2015 ◽  
Vol 135 ◽  
pp. S5-S7
Author(s):  
Franco Piovella ◽  
Diana Irina Iosub
Keyword(s):  
Venous Thromboembolism ◽  
New Anticoagulants

scholarly journals Novel antithrombotic strategies for treatment of venous thromboembolism

Blood ◽  
2020 ◽  
Vol 135 (5) ◽  
pp. 351-359 ◽  
Author(s):  
Jeffrey I. Weitz ◽  
Noel C. Chan
Keyword(s):  
Venous Thromboembolism ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Anticoagulation Therapy ◽  
Chronic Thromboembolic Pulmonary Hypertension ◽  
Postthrombotic Syndrome ◽  
Factor Xii ◽  
Factor Xi ◽  
Vein Thrombosis ◽  
New Anticoagulants

Abstract Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of vascular death after heart attack and stroke. Anticoagulation therapy is the cornerstone of VTE treatment. Despite such therapy, up to 50% of patients with DVT develop postthrombotic syndrome, and up to 4% of patients with PE develop chronic thromboembolic pulmonary hypertension. Therefore, better therapies are needed. Although direct oral anticoagulants are more convenient and safer than warfarin for VTE treatment, bleeding remains the major side effect, particularly in cancer patients. Factor XII and factor XI have emerged as targets for new anticoagulants that may be safer. To reduce the complications of VTE, attenuation of thrombin activatable fibrinolysis inhibitor activity is under investigation in PE patients to enhance endogenous fibrinolysis, whereas blockade of leukocyte interaction with the vessel wall is being studied to reduce the inflammation that contributes to postthrombotic syndrome in DVT patients. Focusing on these novel antithrombotic strategies, this article explains why safer anticoagulants are needed, provides the rationale for factor XII and XI as targets for such agents, reviews the data on the factor XII– and factor XI–directed anticoagulants under development, describes novel therapies to enhance fibrinolysis and decrease inflammation in PE and DVT patients, respectively, and offers insights into the opportunities for these novel VTE therapies.

Sign in / Sign up

Export Citation Format

Share Document